Literature DB >> 1492597

Interferon-gamma (r-IFN-gamma) induced activation of alveolar macrophages (AM) from anergic patients with chronic obstructive pulmonary disease (COPD).

T Todisco1, A Vecchiarelli, M Dottorini, A Eslami, A Bertotto, M Massucci, S Crupi, E Cenci, C Arcangeli, P G Fabietti.   

Abstract

Forty-six anergic patients (37 males and 9 females, age range 55-79 yr) were selected from ninety-one patients suffering from COPD due to frequent exacerbations and impaired delayed cutaneous reactivity (43.9%). The phenotype of circulating lymphocytes, their proliferative response to a panel of polyclonal T-cell activators and the candidacidal activity (CA) of circulating PMNs (polymorphonuclear cells) were measured. In 13 patients presenting a defective CA of circulating PMNs, the in vitro response of alveolar macrophage CA to r-IFN-gamma was also determined. We found: 1) a significant reduction in the CL response to PHA in COPD patients vs controls; 2) a low PMN-CA in 23 (57%) COPD patients; 3) a non-significant difference in phenotype analysis in patients and controls; 4) lower CA of AMs in COPD patients than in controls; 5) restoration in vitro of CA by r-IFN-gamma in the group of anergic COPD patients presenting depressed CA. We conclude that a defective cell-mediated immunity could be the basis of the enhanced susceptibility to infectious exacerbations in many COPD patients and that, in vitro, it could be reversed by r-IFN-gamma treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1492597

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  1 in total

1.  The Notch ligand DNER regulates macrophage IFNγ release in chronic obstructive pulmonary disease.

Authors:  Carolina Ballester-López; Thomas M Conlon; Zeynep Ertüz; Flavia R Greiffo; Martin Irmler; Stijn E Verleden; Johannes Beckers; Isis E Fernandez; Oliver Eickelberg; Ali Önder Yildirim
Journal:  EBioMedicine       Date:  2019-05-04       Impact factor: 8.143

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.